The hallmark of systemic lupus erythematosus (SLE) is the presence of high levels of anti-double-stranded DNA autoantibody (anti-dsDNA) in sera. In addition, pathogen infections coincide frequently with the occurrence of lupus. Our study was designed to investigate the contribution of anti-dsDNA, extracellular and intracellular Toll-like receptors (TLRs), a family of pattern-recognition receptors for sensing invading pathogens, in the pathogenesis of lupus. Although cell surface-expressed TLR4 may promote lupus progression, intracellular nucleic acid-sensing TLR9 plays either stimulatory or protective roles in different murine lupus models. To examine the role of TLR4, TLR9, and anti-dsDNA in SLE, we generated transgenic mice carrying anti-dsDNA antibody transgene and challenged the mice with TLR4- and TLR9-agonists, lipopolysaccharides (LPS), and CpG oligodeoxynucleotide (CpG ODN1826 and 2216), respectively. Splenocytes from these mice were found to secrete higher levels of interleukin-10 (IL-10) and anti-dsDNA when treated with a combination of TLR4 and TLR9 agonists (LPS + CpG). In addition, the transgenic mice were intraperitoneally administered with CpG or combined CpG and LPS to determine whether extracellular TLR4 and intracellular TLR9 activations could affect lupus progression in vivo. It was found that serum levels of anti-dsDNA antibodies and interferon-alpha were higher in CpG + LPS-treated transgenic mice than those in non-transgenic mice. Besides, elevated levels of proteinuria, blood urine nitrogen, and immune complex depositions in kidney were found in treated transgenic mice. Anti-dsDNA and simultaneous activation of surface-expressed TLR4 and endosomal TLR9 are crucial to promote the lupus progression.
RahmanAIsenbergDA. Systemic lupus erythematosus. N Engl J Med2008; 358: 929–929.
2.
ErogluGEKohlerPF. Familial systemic lupus erythematosus: The role of genetic and environmental factors. Ann Rheum Dis2002; 61: 29–29.
3.
BoschXGuilabertAPallaresLCerveralRRamos-CasalsMBoveAIngelmoMFontJ. Infections in systemic lupus erythematosus: A prospective and controlled study of 110 patients. Lupus2006; 15: 584–584.
4.
GladmanDDHussainFIbanezDUrowitzMB. The nature and outcome of infection in systemic lupus erythematosus. Lupus2002; 11: 234–234.
5.
HurstJvonLP. Toll-like receptors and autoimmunity. Autoimmun Rev2008; 7: 204–204.
LiuBYangYDaiJMedzhitovRFreudenbergMAZhangPLLiZ. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol2006; 177: 6880–6880.
8.
LeeTPTangSJWuMFSongYCYuCLSunKH. Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes. J Autoimmun2010; 35: 358–358.
9.
ChristensenSRKashgarianMAlexopoulouLFlavellRAAkiraSShlomchikMJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med2005; 202: 321.–321..
10.
SummersSAHoiASteinmetzOMO’SullivanKMOoiJDOdobasicDAkiraSKitchingARHoldsworthSR. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun2010; 35: 291–291.
ChristensenSRShupeJNickersonKKashgarianMFlavellRAShlomchikMJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity2006; 25: 417–417.
13.
SunKHYuCLTangSJSunGH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology2000; 99: 352–352.
14.
SongYCSunGHLeeTPHuangJCYuCLChenCHTangSJSunKH. Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions. Eur J Immunol2008; 38: 3178–3178.
15.
SongYCTangSJLeeTPHungWCLinSCTsaiCYNgWVWuMFSunKH. Reversing interleukin-2 inhibition mediated by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice. Arthritis Rheum2010; 62: 2401–2401.
16.
SunKHTangSJWangYSLinWJYouRI. Autoantibodies to dsDNA cross-react with the arginine-glycine-rich domain of heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) and promote methylation of hnRNP A2. Rheumatology (Oxford)2003; 42: 154–154.
17.
LuanHYTangSJYangWTsaiCYSunGHSunKH. Monoclonal anti-double-stranded DNA antibodies cross-react with phosphoglycerate kinase 1 and inhibit the expression and production of IL-2 in activated Jurkat T cell line. Clin Immunol2006; 120: 326–326.
18.
WatersSTMcDuffieMBagavantHDeshmukhUSGaskinFJiangCTungKSFuSM. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med2004; 199: 255–255.
19.
YungSChanTM. Anti-DNA antibodies in the pathogenesis of lupus nephritis—the emerging mechanisms. Autoimmun Rev2008; 7: 317–317.
20.
van BavelCCFentonKARekvigOPvan der VlagJBerdenJH. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum2008; 58: 1892–1892.
21.
RekvigOPNossentJC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: A time for new paradigms?Arthritis Rheum2003; 48: 300–300.
22.
ChunHYChungJWKimHAYunJMJeonJYYeYMKimSHParkHSSuhCH. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol2007; 27: 461–461.
23.
BeebeAMCuaDJde WaalMR. The role of interleukin-10 in autoimmune disease: Systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev2002; 13: 403–403.
24.
LlorenteLRichaud-PatinYGarcia-PadillaCClaretEJakez-OcampoJCardielMHAlcocer-VarelaJGrangeot-KerosLAlarcon-SegoviaDWijdenesJGalanaudPEmilieD. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum2000; 43: 1790–1790.
25.
IshidaHMuchamuelTSakaguchiSAndradeSMenonSHowardM. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med1994; 179: 305–305.
26.
LiuTFJonesBM. Impaired production of IL-12 in system lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine1998; 10: 148–148.
BlenmanKRDuanBXuZWanSAtkinsonMAFlotteTRCrokerBPMorelL. IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest2006; 86: 1136–1136.
29.
SuDLLuZMShenMNLiXSunLY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol2012; 2012: 347141–347141.
30.
JacobNGuoSMathianAKossMNGindeaSPuttermanCJacobCOStohlW. B Cell and BAFF dependence of IFN-alpha-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol2011; 186: 4984–4984.
31.
BaccalaRHoebeKKonoDHBeutlerBTheofilopoulosAN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med2007; 13: 543–543.
32.
ThibaultDLGrahamKLLeeLYBalboniIHertzogPJUtzPJ. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res Ther2009; 11: R112–R112.
33.
HeBQiaoXCeruttiA. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol2004; 173: 4479–4479.
34.
Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders HJ, Krug A. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008;58:1107.
35.
Santiago-RaberMLBaudinoLIzuiS. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun2009; 33: 231–231.
36.
ChristensenSRKashgarianMAlexopoulouLFlavellRAAkiraSShlomchikMJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med2005; 202: 321–321.
37.
PawarRDPatolePSEllwartALechMSegererSSchlondorffDAndersHJ. Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol2006; 17: 3365–3365.
38.
EhlersMRavetchJV. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol2007; 28: 74–74.
39.
PapadimitrakiEDTzardiMBertsiasGSotsiouEBoumpasDT. Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: Implications for the amplification of the inflammatory response. Lupus2009; 18: 831–831.
40.
ChenMZhangWXuWZhangFXiongS. Blockade of TLR9 signaling in B cells impaired anti-dsDNA antibody production in mice induced by activated syngenic lymphocyte-derived DNA immunization. Mol Immunol2011; 48: 1532–1532.
41.
De NardoDDe NardoCMNguyenTHamiltonJAScholzGM. Signaling crosstalk during sequential TLR4 and TLR9 activation amplifies the inflammatory response of mouse macrophages. J Immunol2009; 183: 8110–8110.
